Highlights

  • Chimeric Therapeutics (ASX:CHM) reported tumour shrinkage in patients treated at the highest dose level of its CHM-2101 CAR-T trial.
  • Two of four patients at Dose Level 3 recorded individual lesion reductions ranging from 17% to 40%.
  • The Phase 1/2 study is evaluating CDH17 CAR-T therapy in advanced gastrointestinal cancers.
  • Further patient dosing and clinical updates remain key upcoming milestones.

Chimeric Therapeutics (ASX:CHM) has reported further clinical progress from its CHM-2101 CAR-T therapy program, providing early data from its solid-tumour cancer trial.

The company’s latest update highlighted tumour shrinkage observations among patients treated at the highest dose level, representing an important development milestone in a challenging area of oncology research.

However, the data remains early-stage and requires validation through additional patients and longer follow-up.

What Happened?

On 16 July 2026, Chimeric Therapeutics (ASX:CHM) released clinical data from Dose Level 3 of its Phase 1/2 trial evaluating CHM-2101, a third-generation autologous CAR-T cell therapy targeting CDH17.

The trial is assessing patients with advanced gastrointestinal cancers, including colorectal cancer, gastric cancer and intestinal neuroendocrine tumours.

At Dose Level 3, four patients had received treatment at the highest dose of 450 million CAR-T cells.

Two of the four patients recorded tumour shrinkage ranging from 17% to 40% in individual target lesions, with stable disease reported for six months and four months respectively.

The company reported no additional safety signals at the highest dose level beyond a previously disclosed dose-limiting toxicity.

Why It Matters

CAR-T therapies have achieved clinical success in certain blood cancers but have historically faced challenges in solid tumours.

Solid tumours create additional barriers, including limited immune-cell penetration, tumour resistance mechanisms and difficulties maintaining treatment activity.

Chimeric’s approach targets CDH17, a cell-surface protein expressed across several gastrointestinal cancers while having limited expression in many healthy tissues.

The company believes this target may provide an opportunity to develop a CAR-T therapy capable of treating solid tumours while limiting damage to normal tissue.

The Numbers

At Dose Level 3, two of four treated patients experienced individual lesion reductions between 17% and 40%.

These reductions do not automatically meet the RECIST 1.1 criteria for a formal partial response, which generally requires a 30% reduction in the sum of target lesions.

The July update followed earlier data released in May 2026, when Chimeric reported an 82% disease-control rate at the 28-day assessment across nine of 11 evaluable patients across different trial dose levels.

The Phase 1 portion of the trial allows for up to 15 evaluable patients, with follow-up continuing for up to 18 months or until disease progression.

CHM-2101 originated from research conducted at the University of Pennsylvania before being licensed and developed by Chimeric.

The Bigger Picture

Chimeric Therapeutics is developing CAR-T technology in one of the most challenging areas of cancer treatment.

The company’s CDH17 program represents its most advanced clinical asset and is focused on gastrointestinal cancers where treatment Options remain limited for patients who have progressed after standard therapies.

If the therapy demonstrates consistent tumour control in larger patient groups, it could support further development opportunities.

However, current results are based on a small number of patients and require additional clinical evidence before conclusions can be drawn.

The Bull Case

The positive case for Chimeric Therapeutics (ASX:CHM) is based on the potential of CHM-2101 to address limitations that have affected CAR-T approaches in solid tumours.

Early observations of tumour shrinkage at the highest dose level provide preliminary evidence of biological activity.

The CDH17 target provides a mechanism-focused approach in gastrointestinal cancers, and further positive data could support future clinical expansion or Partnership discussions.

Progression through dose escalation also provides additional information on safety and treatment tolerability.

Risks Investors Should Understand

Chimeric Therapeutics (ASX:CHM)’s Business faces risks including early-stage clinical uncertainty, funding requirements, safety challenges and competitive pressure.

The efficacy observations are based on two patients within a four-patient dose cohort, meaning additional data could materially change the interpretation.

Solid-tumour CAR-T therapies face significant development challenges, including potential toxicity and limited durability of responses.

The company has indicated that completion of the highest dose cohort depends on available funding, creating potential Capital requirements and dilution risks.

Regulatory approval remains a lengthy process and clinical-stage outcomes remain uncertain.

What Comes Next?

The next milestones involve treatment of additional patients in the Dose Level 3 cohort and further safety and efficacy follow-up.

Chimeric expects to dose a fifth patient and target a sixth patient in the cohort, subject to funding availability.

Investors will monitor updated clinical results, decisions regarding dose expansion, potential progression into Phase 2 and any financing or partnership developments.

Conclusion

Chimeric Therapeutics (ASX:CHM) has reported early clinical activity from its CHM-2101 CDH17 CAR-T program, with tumour shrinkage observed in patients receiving the highest dose level.

The results provide an early indication of potential activity in solid tumours, an area where CAR-T therapies have historically faced challenges.

However, the data remains based on a small patient group, and future value will depend on additional clinical evidence, funding capacity and the ability to progress the program through later-stage development.